PDCD1 and cancer: Moreover, a vaccine that is based on overlapping HPV E6 and E7 peptides in combination with nivolumab administered to 24 patients with incurable HPV-16–positive cancer showed an ORR of 33% and a median OS of 17.5 month as compared to anti-PD-1 alone [92].